Company / FCF Margin
Dianthus Therapeutics, Inc. /DE/ FCF Margin History
FY2024-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-1308.2%
FY2024
5-year range
-1308.2% / -1308.2%
FY2024-FY2024
Trend
-
vs FY2023
Sector context
#122 of 133
Health Care
What the data says
Among 133 Health Care companies, Dianthus Therapeutics, Inc. /DE/ is in the bottom 8% for fcf margin.
Based on SEC 10-K filings.
-1308.2% in FY2024.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 133This company -1308.2% Sector average -632.8%
▼
-106.7% below sector average
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | -1308.2% | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026